123 related articles for article (PubMed ID: 16732464)
41. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
[TBL] [Abstract][Full Text] [Related]
42. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
43. Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E42-3. PubMed ID: 21677225
[No Abstract] [Full Text] [Related]
44. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
45. Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder.
López-Solà M; Pujol J; Hernández-Ribas R; Harrison BJ; Contreras-Rodríguez O; Soriano-Mas C; Deus J; Ortiz H; Menchón JM; Vallejo J; Cardoner N
Neuropsychopharmacology; 2010 Oct; 35(11):2305-17. PubMed ID: 20668437
[TBL] [Abstract][Full Text] [Related]
46. Duloxetine in the treatment of depression: an overview.
Monteleone F; Caputo M; Tecce MF; Capasso A
Cent Nerv Syst Agents Med Chem; 2011 Sep; 11(3):174-83. PubMed ID: 21919872
[TBL] [Abstract][Full Text] [Related]
47. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial.
Englisch S; Knopf U; Scharnholz B; Kuwilsky A; Deuschle M; Zink M
J Psychopharmacol; 2009 Nov; 23(8):875-82. PubMed ID: 18583440
[TBL] [Abstract][Full Text] [Related]
48. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
[TBL] [Abstract][Full Text] [Related]
49. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
50. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224
[No Abstract] [Full Text] [Related]
51. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
Tomita T; Yasui-Furukori N; Kaneko S
Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
[TBL] [Abstract][Full Text] [Related]
52. Combined use of ECT with duloxetine and olanzapine: a case report.
Hanretta AT; Malek-Ahmadi P
J ECT; 2006 Jun; 22(2):139-41. PubMed ID: 16801831
[TBL] [Abstract][Full Text] [Related]
53. Duloxetine in the acute and continuation treatment of major depressive disorder.
Bochsler L; Olver JS; Norman TR
Expert Rev Neurother; 2011 Nov; 11(11):1525-39. PubMed ID: 22014130
[TBL] [Abstract][Full Text] [Related]
54. False conclusions regarding duloxetine's purported efficacy in pain among depressed patients.
Spielmans GI
Psychiatr Danub; 2010 Dec; 22(4):550; author reply 551. PubMed ID: 21169898
[No Abstract] [Full Text] [Related]
55. Is duloxetine effective treatment for depression with atypical features?
Stewart JW; Deliyannides DA; McGrath PJ
Int Clin Psychopharmacol; 2008 Nov; 23(6):333-6. PubMed ID: 18854721
[TBL] [Abstract][Full Text] [Related]
56. [Interview with Dr. Armin Spingler. Management of depression in family practice].
Spingler A
MMW Fortschr Med; 2010 Nov; 152(44):79. PubMed ID: 21158182
[No Abstract] [Full Text] [Related]
57. Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
Augendre-Ferrante B; Picard H; Evans D; Arkoub H; Pamulapati S; Perrot S; Valensi P; Rouillon F
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):1-7. PubMed ID: 24161159
[TBL] [Abstract][Full Text] [Related]
58. Duloxetine in treatment of anxiety symptoms associated with depression.
Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
[TBL] [Abstract][Full Text] [Related]
59. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
[TBL] [Abstract][Full Text] [Related]
60. Duloxetine may enhance control of pain related to bladder trauma.
Hsu CC; Ku SC; Chang HA; Kao YC; Tzeng NS
Aust N Z J Psychiatry; 2014 Sep; 48(9):881. PubMed ID: 24651062
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
